Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Eye Test Could Lead To Early Detection Of Parkinson’s Disease

XTALKS VITALS NEWS

In addition to helping patients receive an early diagnosis, the technique could be used to monitor patient response to Parkinson’s treatment.

Tweetables from this article:

Tweet: Parkinson’s disease is the second most common neurodegenerative disease worldwide. http://ctt.ec/Bk0s9+ "Parkinson’s disease is the second most common neurodegenerative disease worldwide."

Share this!

August 31, 2016 | by Sarah Massey, M.Sc.

An inexpensive, non-invasive eye test could help physicians diagnose Parkinson’s disease, before the onset of debilitating symptoms, such as muscle stiffness and tremors. Using rat models, researchers at the UCL Institute of Ophthalmology have developed a new method of monitoring retinal changes consistent with the early stages of Parkinson’s.

The method uses ophthalmic instruments to perform optical coherence tomography (OCT) – a technology which is already in use by optometrists and other eye care professionals. The method developed by the researchers was published in the journal, Acta Neuropathologica Communications. In addition to helping patients receive an early diagnosis, the technique could be used to monitor patient response to Parkinson’s treatment. The same technique has been tested on people with glaucoma, and clinical trials involving Alzheimer’s patients are set to start soon.

“This is potentially a revolutionary breakthrough in the early diagnosis and treatment of one of the world's most debilitating diseases,” said study leader Professor Francesca Cordeiro, UCL Professor of Glaucoma & Retinal Neurodegeneration Studies. “These tests mean we might be able to intervene much earlier and more effectively treat people with this devastating condition.”



Parkinson’s disease is the second most common neurodegenerative disease worldwide, with an incidence rate of approximately one in every 500 people. Symptoms of Parkinson’s disease – including tremors, muscle stiffness and slowness of movement – usually do not manifest themselves until nearly three quarters of the brain’s dopamine-secreting cells have been irreversibly damaged.

After visualizing the retinal changes in the rat model of Parkinson’s disease, Cordeiro and her colleagues treated the subjects with a neuroprotectant anti-diabetic drug, Rosiglitazone. The drug was found to reduce retinal cell death, indicating that it could be a potentially promising treatment for Parkinson’s disease.

“These discoveries have the potential to limit and perhaps eliminate the suffering of thousands of patients if we are able to diagnose early and to treat with this new formulation,” said Dr. Eduardo Normando, Consultant Ophthalmologist at Western Eye Hospital and UCL, and primary author on the publication. “The evidence we have strongly suggests that we might be able to intervene much earlier and more effectively in treating people with this devastating condition, using this non-invasive and affordable imaging technique.”


Keywords: Parkinson's Disease, Early Detection, Alzheimer's


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
GSK Malaria Vaccine to be Pilot Tested in Three African Countries

April 25, 2017 - Ghana, Kenya and Malawi will become the first countries to test GlaxoSmithKline’s (GSK) malaria vaccine in 2018.

Featured In: Life Science News


AbbVie Posts Late-Stage Clinical Trial Results for Chronic Hepatitis C Drug

April 24, 2017 - Patients with a traditionally challenging to treat subtype of hepatitis C may soon have a new treatment option for the chronic infection.

Featured In: Clinical Trials News


Study: Few Cardiovascular Benefits of Aspirin Therapy for Patients with Peripheral Vascular Disease

April 24, 2017 - A new study conducted by researchers at the University of Florida has found that aspirin therapy may not provide sufficient cardiovascular benefits for patients with peripheral vascular disease.

Featured In: Clinical Trials News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

A Holistic Understanding of the Patient Journey Using Multiple Data Sources


Addressing the Challenges of Type II Diabetes Global Clinical Trials via Use of High Quality Laboratory Solutions


Clinical Trial Considerations in Cerebral Protection for TAVR Patients


Enabling Multi-Analyte Analysis of Lung Cancer FFPE Samples with 3D Biology™ Technology


Copyright © 2016-2017 Honeycomb Worldwide Inc.